Relationship Between Vitamin D and Metabolic Associated Fatty Liver Disease and Its Mechanism

CHEN Danni; WANG Shiling; LU Hong; ZHENG Ya; WANG Yuping; REN Qian

doi:10.12290/xhyxzz.2023-0075

Volume 14 Issue 6

Nov. 2023

Turn off MathJax

Article Contents

Abstract

References

Medical Journal of Peking Union Medical College Hospital > 2023 > 14(6): 1258-1265. > DOI: 10.12290/xhyxzz.2023-0075

CHEN Danni, WANG Shiling, LU Hong, ZHENG Ya, WANG Yuping, REN Qian. Relationship Between Vitamin D and Metabolic Associated Fatty Liver Disease and Its Mechanism[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(6): 1258-1265. DOI: 10.12290/xhyxzz.2023-0075

Citation:

Relationship Between Vitamin D and Metabolic Associated Fatty Liver Disease and Its Mechanism

CHEN Danni^{1, 2},
WANG Shiling^{1, 2},
LU Hong^{2, 3},
ZHENG Ya^{2, 4},
WANG Yuping^{2, 4},
REN Qian^{2, 3, 4, ,}

1.
The First Clinical Medical College of Lanzhou University, Lanzhou 730000, China
2.
Department of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou 730000, China
3.
Digestive Endoscope Center, The First Hospital of Lanzhou University, Lanzhou 730000, China
4.
Gansu Province Clinical Research Center for Digestive Diseases, The First Hospital of Lanzhou University, Lanzhou 730000, China

Funds:

Natural Science Foundation of Gansu Province 21JR7RA381

Health Industry Research Project of Gansu Province GSWSKY2020-07

Fundamental Research Funds for the Central Universities lzujbky-2021-ct17

Hospital Foundation of Lanzhou University First Hospital ldyyyn2019-74

More Information

Corresponding author:
REN Qian, E-mail: ldyy_renqian@lzu.edu.cn
Received Date: February 12, 2023
Accepted Date: June 18, 2023
Available Online: August 03, 2023
Issue Publish Date: November 29, 2023

Graphical Abstract

Abstract

Abstract

Metabolic associated fatty liver disease (MAFLD) was renamed from the nonalcoholic fatty liver disease (NAFLD). In terms of the pathogenesis of MAFLD, the generally accepted theory is "multiple attacks", including insulin resistance, lipid disorder, oxidative stress, intestinal microbiota, etc., which involves the interaction of genetic and environmental factors. However, currently there is no approved drug for MAFLD. Recent studies have found that vitamin D is involved in many metabolic processes and may cause MAFLD by influencing liver lipid metabolism, promoting insulin resistance and inflammatory response, participating in immune regulation, gene regulation and maintaining intestinal homeostasis. Therefore, this article summarizes the relationship between vitamin D and MAFLD, explores the potential role of vitamin D in the pathogenesis of MAFLD, and provides clinical ideas for the treatment of MAFLD.
- vitamin D,
- metabolic associated fatty liver disease,
- vitamin D receptor

FullText(HTML)

References (68)

References

[1]	Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement[J]. J Hepatol, 2020, 73: 202-209. DOI: 10.1016/j.jhep.2020.03.039
[2]	Paik JM, Golabi P, Younossi Y, et al. Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD[J]. Hepatology, 2020, 72: 1605-1616. DOI: 10.1002/hep.31173
[3]	Wong RJ, Cheung R. Trends in the Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in the United States, 2011—2018[J]. Clin Gastroenterol Hepatol, 2022, 20: e610- e613. DOI: 10.1016/j.cgh.2021.01.030
[4]	Charoenngam N, Holick MF. Immunologic Effects of Vitamin D on Human Health and Disease[J]. Nutrients, 2020, 12: 2097. DOI: 10.3390/nu12072097
[5]	Szymczak-Pajor I, Drzewoski J, Śliwińska A. The Molecular Mechanisms by Which Vitamin D Prevents Insulin Resis-tance and Associated Disorders[J]. Int J Mol Sci, 2020, 21: 6644. DOI: 10.3390/ijms21186644
[6]	Jiang Z, Pu R, Li N, et al. High prevalence of vitamin D deficiency in Asia: A systematic review and meta-analysis[J]. Crit Rev Food Sci Nutr, 2021: 1-10.
[7]	Rimondi E, Marcuzzi A, Casciano F, et al. Role of vitamin D in the pathogenesis of atheromatosis[J]. Nutr Metab Cardiovasc Dis, 2021, 31: 344-353. DOI: 10.1016/j.numecd.2020.08.031
[8]	Dawson-Hughes B, Staten MA, Knowler WC, et al. Intratrial Exposure to Vitamin D and New-Onset Diabetes Among Adults With Prediabetes: A Secondary Analysis From the Vitamin D and Type 2 Diabetes (D2d) Study[J]. Diabetes Care, 2020, 43: 2916-2922. DOI: 10.2337/dc20-1765
[9]	Yu S, Song L, Wei Q, et al. Dose-response relationship between serum 25-hydroxyvitamin D and the risk of metabolic syndrome[J]. Clin Nutr, 2021, 40: 1530-1536. DOI: 10.1016/j.clnu.2021.02.031
[10]	Cimini FA, Barchetta I, Carotti S, et al. Overview of studies of the vitamin D/vitamin D receptor system in the development of non-alcoholic fatty liver disease[J]. World J Gastrointest Pathophysiol, 2019, 10: 11-16. DOI: 10.4291/wjgp.v10.i2.11
[11]	Yuan S, Larsson SC. Inverse Association Between Serum 25-Hydroxyvitamin D and Nonalcoholic Fatty Liver Disease[J]. Clin Gastroenterol Hepatol, 2023, 21: 398-405. e4. DOI: 10.1016/j.cgh.2022.01.021
[12]	Zhang JJ, Yu HC, Li Y, et al. Association between serum 25-hydroxy vitamin D concentrations and mortality among individuals with metabolic dysfunction-associated fatty liver disease: a prospective cohort study[J]. Am J Clin Nutr, 2022, 116: 1409-1417. DOI: 10.1093/ajcn/nqac260
[13]	Fan X, Wang J, Song M, et al. Vitamin D Status and Risk of All-Cause and Cause-Specific Mortality in a Large Cohort: Results From the UK Biobank[J]. J Clin Endocrinol Metab, 2020, 105: dgaa432.
[14]	Luo L, Ye J, Shao C, et al. Vitamin D Status Presents Different Relationships with Severity in Metabolic-Associated Fatty Liver Disease Patients with or without Hepatitis B Infection[J]. Nutrients, 2022, 14: 2114. DOI: 10.3390/nu14102114
[15]	周荃, 李金强, 黎晓武. 维生素D缺乏对非酒精性脂肪性肝炎患者FIB-4指数及病情严重程度的影响[J]. 临床肝胆病杂志, 2022, 38: 1293-1298. https://www.cnki.com.cn/Article/CJFDTOTAL-LCGD202206015.htm
[16]	Ha Y, Hwang SG, Rim KS. The Association between Vitamin D Insufficiency and Nonalcoholic Fatty Liver Disease: A Population-Based Study[J]. Nutrients, 2017, 9: 806. DOI: 10.3390/nu9080806
[17]	Patel YA, Henao R, Moylan CA, et al. Vitamin D is Not Associated With Severity in NAFLD: Results of a Paired Clinical and Gene Expression Profile Analysis[J]. Am J Gastroenterol, 2016, 111: 1591-1598. DOI: 10.1038/ajg.2016.406
[18]	Manson JE, Cook NR, Lee IM, et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease[J]. N Engl J Med, 2019, 380: 33-44. DOI: 10.1056/NEJMoa1809944
[19]	Neale RE, Baxter C, Romero BD, et al. The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality[J]. Lancet Diabetes Endocrinol, 2022, 10: 120-128. DOI: 10.1016/S2213-8587(21)00345-4
[20]	Wang N, Chen C, Zhao L, et al. Vitamin D and Nonalcoholic Fatty Liver Disease: Bi-directional Mendelian Randomization Analysis[J]. EbioMedicine, 2018, 28: 187-193. DOI: 10.1016/j.ebiom.2017.12.027
[21]	El Khoudary SR, Samargandy S, Zeb I, et al. Serum 25-hydroxyvitamin-D and nonalcoholic fatty liver disease: Does race/ethnicity matter? Findings from the MESA cohort[J]. Nutr Metab Cardiovasc Dis, 2020, 30: 114-122. DOI: 10.1016/j.numecd.2019.09.004
[22]	Lukenda Zanko V, Domislovic V, Trkulja V, et al. Vitamin D for treatment of non-alcoholic fatty liver disease detected by transient elastography: A randomized, double-blind, placebo-controlled trial[J]. Diabetes Obes Metab, 2020, 22: 2097-2106. DOI: 10.1111/dom.14129
[23]	El Amrousy D, Abdelhai D, Shawky D. Vitamin D and nonalcoholic fatty liver disease in children: a randomized controlled clinical trial[J]. Eur J Pediatr, 2022, 181: 579-586. DOI: 10.1007/s00431-021-04243-4
[24]	Gad AI, Elmedames MR, Abdelhai AR, et al. Efficacy of vitamin D supplementation on adult patients with non-alcoholic fatty liver disease: a single-center experience[J]. Gastroenterol Hepatol Bed Bench, 2021, 14: 44-52.
[25]	Rezaei S, Tabrizi R, Nowrouzi-Sohrabi P, et al. The Effects of Vitamin D Supplementation on Anthropometric and Biochemical Indices in Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis[J]. Front Pharmacol, 2021, 12: 732496. DOI: 10.3389/fphar.2021.732496
[26]	Rasouli N, Brodsky IG, Chatterjee R, et al. Effects of Vitamin D Supplementation on Insulin Sensitivity and Secretion in Prediabetes[J]. J Clin Endocrinol Metab, 2022, 107: 230-240. DOI: 10.1210/clinem/dgab649
[27]	Wei Y, Wang S, Meng Y, et al. Effects of Vitamin D Supplementation in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis[J]. Int J Endocrinol Metab, 2020, 18: e97205.
[28]	Carlberg C, Haq A. The concept of the personal vitamin D response index[J]. J Steroid Biochem Mol Biol, 2018, 175: 12-17. DOI: 10.1016/j.jsbmb.2016.12.011
[29]	Triantos C, Aggeletopoulou I, Thomopoulos K, et al. Vitamin D-Liver Disease Association: Biological Basis and Mechanisms of Action[J]. Hepatology, 2021, 74: 1065-1073. DOI: 10.1002/hep.31699
[30]	Udomsinprasert W, Jittikoon J. Vitamin D and liver fibrosis: Molecular mechanisms and clinical studies[J]. Biomed Pharmacother, 2019, 109: 1351-1360. DOI: 10.1016/j.biopha.2018.10.140
[31]	Lockau L, Atkinson SA. Vitamin D's role in health and disease: How does the present inform our understanding of the past?[J]. Int J Paleopathol, 2018, 23: 6-14. DOI: 10.1016/j.ijpp.2017.11.005
[32]	Dong B, Zhou Y, Wang W, et al. Vitamin D Receptor Activation in Liver Macrophages Ameliorates Hepatic Inflammation, Steatosis, and Insulin Resistance in Mice[J]. Hepatology, 2020, 71: 1559-1574. DOI: 10.1002/hep.30937
[33]	Zhang H, Shen Z, Lin Y, et al. Vitamin D receptor targets hepatocyte nuclear factor 4α and mediates protective effects of vitamin D in nonalcoholic fatty liver disease[J]. J Biol Chem, 2020, 295: 3891-3905. DOI: 10.1074/jbc.RA119.011487
[34]	Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)[J]. Metabolism, 2016, 65: 1038-1048. DOI: 10.1016/j.metabol.2015.12.012
[35]	Marziou A, Philouze C, Couturier C, et al. Vitamin D Supplementation Improves Adipose Tissue Inflammation and Reduces Hepatic Steatosis in Obese C57BL/6J Mice[J]. Nutrients, 2020, 12: 342. DOI: 10.3390/nu12020342
[36]	Szymczak-Pajor I, Śliwińska A. Analysis of Association between Vitamin D Deficiency and Insulin Resistance[J]. Nutrients, 2019, 11: 794. DOI: 10.3390/nu11040794
[37]	Zeng Y, Luo M, Pan L, et al. Vitamin D signaling maintains intestinal innate immunity and gut microbiota: potential intervention for metabolic syndrome and NAFLD[J]. Am J Physiol Gastrointest Liver Physiol, 2020, 318: G542-G553. DOI: 10.1152/ajpgi.00286.2019
[38]	Surdu AM, Pînzariu O, Ciobanu DM, et al. Vitamin D and Its Role in the Lipid Metabolism and the Development of Atherosclerosis[J]. Biomedicines, 2021, 9: 172. DOI: 10.3390/biomedicines9020172
[39]	Li R, Guo E, Yang J, et al. 1, 25(OH)₂D₃ attenuates hepatic steatosis by inducing autophagy in mice[J]. Obesity (Silver Spring), 2017, 25: 561-571. DOI: 10.1002/oby.21757
[40]	Lim H, Lee H, Lim Y. Effect of vitamin D₃ supplementa-tion on hepatic lipid dysregulation associated with autophagy regulatory AMPK/Akt-mTOR signaling in type 2 diabetic mice[J]. Exp Biol Med (Maywood), 2021, 246: 1139-1147. DOI: 10.1177/1535370220987524
[41]	Borges CC, Salles AF, Bringhenti I, et al. Vitamin D Deficiency Increases Lipogenesis and Reduces Beta-Oxidation in the Liver of Diet-Induced Obese Mice[J]. J Nutr Sci Vitaminol (Tokyo), 2018, 64: 106-115. DOI: 10.3177/jnsv.64.106
[42]	Marino M, Venturi S, Del Bo C, et al. Vitamin D Counteracts Lipid Accumulation, Augments Free Fatty Acid-Induced ABCA1 and CPT-1A Expression While Reducing CD36 and C/EBPβ Protein Levels in Monocyte-Derived Macrophages[J]. Biomedicines, 2022, 10: 775. DOI: 10.3390/biomedicines10040775
[43]	Hosny SS, Ali HM, Mohammed WA, et al. Study of relationship between total vitamin D level and NAFLD in a sample of Egyptian patients with and without T2DM[J]. Diabetes Metab Syndr, 2019, 13: 1769-1771. DOI: 10.1016/j.dsx.2019.04.002
[44]	Manna P, Jain SK. Vitamin D up-regulates glucose transporter 4 (GLUT4) translocation and glucose utilization mediated by cystathionine-γ-lyase (CSE) activation and H2S formation in 3T3L1 adipocytes[J]. J Biol Chem, 2012, 287: 42324-42332. DOI: 10.1074/jbc.M112.407833
[45]	Elseweidy MM, Amin RS, Atteia HH, et al. Vitamin D3 intake as regulator of insulin degrading enzyme and insulin receptor phosphorylation in diabetic rats[J]. Biomed Pharmacother, 2017, 85: 155-159. DOI: 10.1016/j.biopha.2016.11.116
[46]	Borges CC, Salles AF, Bringhenti I, et al. Adverse effects of vitamin D deficiency on the Pi3k/Akt pathway and pancreatic islet morphology in diet-induced obese mice[J]. Mol Nutr Food Res, 2016, 60: 346-357. DOI: 10.1002/mnfr.201500398
[47]	Li YC, Kong J, Wei M, et al. 1, 25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system[J]. J Clin Invest, 2002, 110: 229-238. DOI: 10.1172/JCI0215219
[48]	Gutierrez-Rodelo C, Arellano-Plancarte A, Hernandez-Aranda J, et al. Angiotensin Ⅱ Inhibits Insulin Receptor Signaling in Adipose Cells[J]. Int J Mol Sci, 2022, 23: 6048. DOI: 10.3390/ijms23116048
[49]	Roth CL, Elfers CT, Figlewicz DP, et al. Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and Toll-like receptor activation[J]. Hepatology, 2012, 55: 1103-1111. DOI: 10.1002/hep.24737
[50]	Liu Y, Wang M, Xu W, et al. Active vitamin D supplementation alleviates initiation and progression of nonalcoholic fatty liver disease by repressing the p53 pathway[J]. Life Sci, 2020, 241: 117086. DOI: 10.1016/j.lfs.2019.117086
[51]	Zhang X, Shang X, Jin S, et al. Vitamin D ameliorates high-fat-diet-induced hepatic injury via inhibiting pyroptosis and alters gut microbiota in rats[J]. Arch Biochem Biophys, 2021, 705: 108894. DOI: 10.1016/j.abb.2021.108894
[52]	Wang H, Mehal W, Nagy LE, et al. Immunological mechanisms and therapeutic targets of fatty liver diseases[J]. Cell Mol Immunol, 2021, 18: 73-91. DOI: 10.1038/s41423-020-00579-3
[53]	Ortiz-López N, Fuenzalida C, Dufeu MS, et al. The immune response as a therapeutic target in non-alcoholic fatty liver disease[J]. Front Immunol, 2022, 13: 954869. DOI: 10.3389/fimmu.2022.954869
[54]	Sîrbe C, Rednic S, Grama A, et al. An Update on the Effects of Vitamin D on the Immune System and Autoimmune Diseases[J]. Int J Mol Sci, 2022, 23: 9784. DOI: 10.3390/ijms23179784
[55]	Czaja AJ, Montano-Loza AJ. Evolving Role of Vitamin D in Immune-Mediated Disease and Its Implications in Autoimmune Hepatitis[J]. Dig Dis Sci, 2019, 64: 324-344. DOI: 10.1007/s10620-018-5351-6
[56]	Barrea L, Muscogiuri G, Frias-Toral E, et al. Nutrition and immune system: from the Mediterranean diet to dietary supplementary through the microbiota[J]. Crit Rev Food Sci Nutr, 2021, 61: 3066-3090. DOI: 10.1080/10408398.2020.1792826
[57]	Su YB, Li TH, Huang CC, et al. Chronic calcitriol supplementation improves the inflammatory profiles of circulating monocytes and the associated intestinal/adipose tissue alteration in a diet-induced steatohepatitis rat model[J]. PLoS One, 2018, 13: e0194867. DOI: 10.1371/journal.pone.0194867
[58]	Tourkochristou E, Mouzaki A, Triantos C. Gene Polymorphisms and Biological Effects of Vitamin D Receptor on Nonalcoholic Fatty Liver Disease Development and Progression[J]. Int J Mol Sci, 2023, 24: 8288. DOI: 10.3390/ijms24098288
[59]	García-Monzón C, Petrov PD, Rey E, et al. Angiopoietin-Like Protein 8 Is a Novel Vitamin D Receptor Target Gene Involved in Nonalcoholic Fatty Liver Pathogenesis[J]. Am J Pathol, 2018, 188: 2800-2810. DOI: 10.1016/j.ajpath.2018.07.028
[60]	Jaroenlapnopparat A, Suppakitjanusant P, Ponvilawan B, et al. Vitamin D-Related Genetic Variations and Nonalco-holic Fatty Liver Disease: A Systematic Review[J]. Int J Mol Sci, 2022, 23: 9122. DOI: 10.3390/ijms23169122
[61]	Arai T, Atsukawa M, Tsubota A, et al. Association of vitamin D levels and vitamin D-related gene polymorphisms with liver fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease[J]. Dig Liver Dis, 2019, 51: 1036-1042. DOI: 10.1016/j.dld.2018.12.022
[62]	Wang M, Wang M, Zhang R, et al. Influences of Vitamin D Levels and Vitamin D-Binding Protein Polymorphisms on Nonalcoholic Fatty Liver Disease Risk in a Chinese Population[J]. Ann Nutr Metab, 2022, 78: 61-72. DOI: 10.1159/000522193
[63]	Leung C, Rivera L, Furness JB, et al. The role of the gut microbiota in NAFLD[J]. Nat Rev Gastroenterol Hepatol, 2016, 13: 412-425.
[64]	Barbáchano A, Fernández-Barral A, Ferrer-Mayorga G, et al. The endocrine vitamin D system in the gut[J]. Mol Cell Endocrinol, 2017, 453: 79-87.
[65]	He L, Liu T, Shi Y, et al. Gut Epithelial Vitamin D Receptor Regulates Microbiota-Dependent Mucosal Inflamma-tion by Suppressing Intestinal Epithelial Cell Apoptosis[J]. Endocrinology, 2018, 159: 967-979.
[66]	Singh P, Rawat A, Alwakeel M, et al. The potential role of vitamin D supplementation as a gut microbiota modifier in healthy individuals[J]. Sci Rep, 2020, 10: 21641.
[67]	Kong M, Zhu L, Bai L, et al. Vitamin D deficiency promotes nonalcoholic steatohepatitis through impaired enterohepatic circulation in animal model[J]. Am J Physiol Gastrointest Liver Physiol, 2014, 307: G883- G893.
[68]	Lee PC, Hsieh YC, Huo TI, et al. Active Vitamin D₃ Treatment Attenuated Bacterial Translocation via Improving Intestinal Barriers in Cirrhotic Rats[J]. Mol Nutr Food Res, 2021, 65: e2000937.

Cited By

Cited by

Periodical cited type(4)

1.	窦紫岩，钱文红，孔邻润，陈晔，李明亮，张静波. 非酒精性脂肪性肝病检出率现状及其影响因素：基于北京市32万人群数据. 中国全科医学. 2024(02): 144-149+155 .
2.	王伟，缪海江，王新宇. 木香流气饮联合多烯磷脂酰胆碱胶囊对非酒精性脂肪肝肝郁脾虚证患者的效果观察. 深圳中西医结合杂志. 2024(06): 46-49 .
3.	韩炜，宋叶君，张改萍，田晓英，付素芳，赵芳，王俊，周冉，张思宇，杜金星. 非酒精性脂肪肝病人健康减重的证据总结. 全科护理. 2024(23): 4450-4453 .
4.	吴风，孔丽蕊，谭志群. 2型糖尿病合并NAFLD患者铁蛋白、TyG-BMI变化及与脂肪变性程度的相关性. 新疆医科大学学报. 2023(10): 1338-1343 .

Other cited types(2)

Get Citation

XML

Article Metrics

Article views (521) PDF downloads (84) Cited by(6)

Address：	Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
Tel：	010-69154261/4262
E - mail：	medj@pumch.cn mjpumch@126.com
Copyright of website：	Editorial Office of Medical Journal of Peking Union Medical College Hospital

Relationship Between Vitamin D and Metabolic Associated Fatty Liver Disease and Its Mechanism

Abstract

References

Cited by

Periodical cited type(4)

Other cited types(2)

Catalog

Article Metrics

Related

Export File

Citation

Format

Content